SCHEMBL2293159

SCHEMBL2293159

C=CCN1C[C@H](c2ccc(OCc3ccccc3)cc2)OCC1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.43
MAOB P27338 2/20 0.42
TP53 P04637 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
SETDB1 Q15047 1/20 0.41
SIRT1 Q96EB6 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40
MMP13 P45452 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
MAOA P21397 1/20 0.40
HSD17B10 Q99714 1/20 0.39
S1PR5 Q9H228 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293787 1.00 GRM2 (0.43) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL322596 0.86 GRM2 (0.55) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2295623 0.86 GRM2 (0.55) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2293382 0.86 GRM2 (0.55) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2295254 0.85 GRM2 (0.48) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2297986 0.85 GRM2 (0.48) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2296694 0.84 HRH3 (0.46) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL2297420 0.84 HRH3 (0.46) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL3160475 0.83 GRM2 (0.47) GRM2MAOBTP53OPRM1OPRD1
SCHEMBL1438895 0.82 FFAR1 (0.46) GRM2TP53MMP13MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US claimed
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
EP-2221305-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
EP-2221304-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 GRM2 1252/4885MAOB 653/4885TP53 1955/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 GRM2 1252/4885MAOB 653/4885TP53 1955/4885
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 GRM2 1252/4885MAOB 653/4885TP53 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.